Maryland Daily Record Maryland's trusted source for business and legal news
Dr. Bahija Jallal
Bahija Jallal, Ph.D., executive vice president of research and development at MedImmune, has been named to the board of directors of the UM Health Sciences Research Park Corp. Jallal is a member of MedImmune’s executive team and of the research and development leadership team of parent company AstraZeneca.
She oversees research, development, regulatory and clinical activities conducted by a team of more than 2,500 MedImmune employees in Maryland, California and the United Kingdom and has guided R&D through the expansion of its biologics pipeline from 40 drugs to more than 140.
Jallal received a master’s in biology from the Universite de Paris VII in France and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.
